CD19 and Miyoshi myopathy: According to a clinical study by Garfall and colleagues (NCT02135406), 2 out of 10 patients (20%) with R/R MM underwent CD19-redirected CAR-T therapy (CLT019) following autologous stem cell transplantation (ASCT) and melphalan-based salvage therapy, and experienced remarkably more prolonged PFS than when they only underwent ASCT as prior therapy (479 versus 181 days for one patient, and 249 versus 127 days for the other, respectively) (51).